Axl expression is associated with adverse prognosis and with expression of Bcl-2 and CD34 in de novo acute myeloid leukemia (AML): results from a multicenter trial of the Swiss Group for Clinical Cancer Research (SAKK) (Q78247911)
Jump to navigation
Jump to search
scientific article published on 01 September 1999
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Axl expression is associated with adverse prognosis and with expression of Bcl-2 and CD34 in de novo acute myeloid leukemia (AML): results from a multicenter trial of the Swiss Group for Clinical Cancer Research (SAKK) |
scientific article published on 01 September 1999 |
Statements
Axl expression is associated with adverse prognosis and with expression of Bcl-2 and CD34 in de novo acute myeloid leukemia (AML): results from a multicenter trial of the Swiss Group for Clinical Cancer Research (SAKK) (English)
C Rochlitz
A Lohri
M Bacchi
M Schmidt
S Nagel
M Fopp
M F Fey
R Herrmann
1 September 1999